Table 1.
Clinicopathological features and basic characteristics.
| Variables | Entire (n = 33) | Placebo (n = 17) | Royal Jelly (n = 16) | p Value |
|---|---|---|---|---|
| Age | 0.101 | |||
| Mean ± SD, years | 67.6 ± 6.6 | 65.8 ± 8.8 | 69.6 ± 5.9 | |
| Gender; n (%) | 0.909 | |||
| Male/Female | 23/10 (30.3) | 12/5 (29.4) | 11/5 (31.3) | |
| Performance Status | 0.598 | |||
| 0/1 | 16/17 (51.5) | 9/8 (47.1) | 7/9 (56.3) | |
| Pathological Type | 0.446 | |||
| Conventional | 29 (87.9) | 16 (94.1) | 13 (81.3) | |
| Fuhrman Grade | 0.425 | |||
| 1 or 2/3 or 4 | 6/27 (81.8) | 2/15 (88.2) | 4/12 (75.0) | |
| pT stage | 0.201 | |||
| 1 or 2/3 or 4 | 9/24 (72.7) | 3/14 (82.4) | 6/10 (62.5) | |
| Lymph Node Metastasis | 0.881 | |||
| Presence | 19 (57.6) | 10 (58.8) | 9 (56.3) | |
| Distant Metastasis | 0.325 | |||
| Presence | 27 (81.8) | 15 (88.2) | 12 (75.0) | |
| Neo-Adjuvant Setting | 0.965 | |||
| Yes | 2 (6.1) | 1 (5.9) | 1 (6.3) | |
| Past Therapy Used TKI | 0.948 | |||
| Presence | 4 (12.1) | 2 (11.8) | 2 (12.5) | |
| TKIs | 0.539 | |||
| Sunitinib | 21 (63.6) | 11 (64.7) | 10 (62.5) | |
| Pazopanib | 7 (21.2) | 3 (17.6) | 4 (25.0) | |
| Axitinib | 4 (12.1) | 3 (17.6) | 1 (6.3) | |
| Sorafenib | 1 (3.0) | 0 (0.0) | 1 (6.3) |
TKIs = tyrosine kinase inhibitors. SD = standard deviation.